All Posts By

interactive@smallbusinessmiracles.com

$4 Million Animal Health Investment Means More Strides for Treating Diabetic Pets

By | News & Media | No Comments

Werth Family Investment Associates backs Likarda’s proprietary Kanslet™ diabetes treatment in dogs and cats.

 

KANSAS CITY, Kan. – Cutting-edge biotech research laboratory, Likarda, has received $4,000,000 in Series A funding from Werth Family Investment Associates, bringing the promise of future diabetes treatment options to dogs and cats.

Likarda is the leading regenerative medicine company for companion animals. They have discovered—and are commercializing—a better way to manage diabetes in dogs and cats. Their insulin-producing cell clusters, called the Kanslet™, can be infused into animals with diabetes. The process allows veterinarians to offer a minimally invasive, cost-effective answer to pet owners battling the burden of diabetes in dogs and cats.

Read More

Likarda Outgrows Space at KU Incubator

By | News & Media | No Comments

Biotech research lab continues promising growth with move.

 

KANSAS CITY, Kan. – Cutting-edge biotech research laboratory Likarda has outgrown its space at the Bioscience & Technology Business Center (BTBC) on the KU Medical Center Campus and will move near the former Marion Laboratories campus in south Kansas City, Missouri, in October 2017. The move more than doubles the square footage of their former laboratory space, allowing Likarda to continue to scale up operations.

Likarda has occupied lab space at the BTBC since they were founded in May 2012. Since that time, their success as a pharmaceutical contract research organization and pioneer in animal health has seen the lab space grow to encompass the ground floor of the BTBC. As the race is constant to bring new drugs to market, pharmaceutical and nutraceutical companies and science entrepreneurs turn to contract research organizations (CROs) like Likarda to provide or supplement the research process.

Read More

Likarda featured on SelectScience.net

By | News & Media | No Comments

Automating Assay Development for Early Stage Drug Discovery

Likarda works with clients at the early stages of drug development and discovery.  Dr Lisa Stehno-Bittel, President & Co-founder of Likarda, discusses how the company develops 3D cell clusters, which are indicative of native tissues in the body, for use in cell-based assays. Hear from research scientist Stephen Harrington PhD, Likarda’s Director of Production, how the team has utilized automation to increase throughput and reproducibility, most recently employing the Integra Assist to bridge the gap between manual bench work and complete automation. Read More

Understanding CRO 3.0

By | News & Media, Uncategorized | No Comments

Understanding the past, present and future roles of CROs in early phase drug discovery

As the race is constant to bring new drugs to market, pharmaceutical and nutraceutical companies and science entrepreneurs turn to contract research organizations (CROs) to provide or supplement research processes. This puts an emphasis on providing pharma and entrepreneurs with custom assays, tools and information that improve their workflow efficiency and speed to market. This article examines how CROs influence the research environment and how they can alter their roles to support pharma and science entrepreneurs in intense market competition, reducing the exorbitant time and cost associated with early phase drug discovery. It explores the roles of CROs’ progression in helping pharma and entrepreneurs move confidently forward from the early discovery phase in the past, now and in the future. Read More

Buzz for BIO: Moving Early-Phase Discovery Forward with Confidence

By | News & Media | No Comments

Custom 3D Assays and Research Services Result in Better Predictability of Drug Treatment Response

Using our proprietary 3D screening approach, Likarda researchers test different drugs with known effects in humans using the conventional pharmaceutical approach and our 3D cell cluster. In each case, the results of our 3D assays better mimicked how the drugs work in humans. Compared to conventional methods, our process allows you to better predict responses to drug treatments. And as a CRO, our turnaround time and costs are more efficient. Read More